Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Glycopyrrolate/indacaterol/mometasone - Novartis

Next Previous
Drug Profile

Glycopyrrolate/indacaterol/mometasone - Novartis

Alternative Names: Enerzair; Enerzair Breezhaler; ICS/LABA/LAMA inhaled triple therapy - Novartis; IND/GLY/MF; Indacaterol acetate, glycopyrronium bromide and mometasone furoate - Novartis; QVM 149

Latest Information Update: 02 Apr 2024

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Sosei Heptares; Vectura
  • Developer Novartis
  • Class Anti-inflammatories; Antiallergics; Antiasthmatics; Bronchodilators; Corticosteroids; Glucocorticoids; Indans; Pregnadienediols; Pyrrolidines; Quaternary ammonium compounds; Quinolones; Small molecules
  • Mechanism of Action Beta 2 adrenergic receptor agonists; Glucocorticoid receptor agonists; Muscarinic receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Asthma

Most Recent Events

  • 31 Mar 2024 Sosei Heptares is now called Nxera Pharma
  • 20 Mar 2023 Novartis Pharmaceuticals plans a phase III trial for Asthma (In children, In adolescents, Treatment-experienced) in (Inhalation) in June 2022 (NCT05776927)
  • 29 Dec 2022 University Medical Center Groningen and Novartis completes a phase III trial in Asthma in Netherlands (NCT04259164)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top